This guide explains why it does not present a figure as UK fact, how to read trial averages for licensed semaglutide sensibly, and why results are individual and depend on diet and activity. It is grounded in the UK-licensed injection and is general information framed around averages and variation rather than guarantees.
Why we don't quote a results figure
Any specific weight-loss percentage for the Wegovy pill that is circulating now comes from outside the UK licence and the regulated UK sources this guide relies on 3. Because the pill is not yet UK-licensed, there is no UK-confirmed results picture for it, so presenting a figure as settled UK fact would be misleading 3.
This is the same principle this guide applies to dose and safety: efficacy claims should come from UK-regulated product information and from NICE, which for an unlicensed product do not yet exist 3. Trial data reported elsewhere is part of the evidence regulators consider, not a substitute for a UK licence 3.
So rather than a number that could mislead, this page explains how to think about results for this kind of medicine: as averages, with wide individual variation, achieved alongside diet and activity 1. That is the honest and useful basis while the pill remains under review 3.
Averages are not guarantees
The figures that exist for weight-loss medicines come from clinical trials, and they are averages across groups of people, not a promise for any individual 1. An average is useful for setting expectations, but it hides a wide spread: some people lose more, some less, and where you fall depends on many factors 1.
So even once the Wegovy pill is licensed and has a UK results picture, the right way to read any headline figure will be 'what the trials averaged', not 'what you will achieve' 1. That is not hedging; it is the accurate way to present trial data and protects you from the disappointment a single promised number can create 1.
This is also why responsible guidance avoids before-and-after style guarantees 1. The useful thing is a realistic range and an understanding of what shifts your own result, which depends as much on the diet and activity alongside the medicine as on the medicine itself 1.
Results depend on diet and activity
Semaglutide is licensed to be used as an adjunct to a reduced-calorie diet and increased physical activity, and the trial results reflect that whole package, not the medicine alone 1. The appetite effect makes eating less more achievable, but the result still depends on what you do alongside it 1.
The NHS likewise frames semaglutide as something used with diet and exercise 2. So a realistic results picture is one where the medicine supports your efforts, and those efforts remain part of the outcome rather than being replaced 12.
This matters for expectations about the pill specifically 1. Whatever its UK results picture turns out to be, it would, like the injection, reflect use alongside diet and activity, so the same principle applies: the medicine is a powerful support, not a standalone fix 13.
Want to know when the Wegovy pill (oral semaglutide) becomes available in the UK? It is not yet licensed here, but you can join the waitlist to be notified, and explore the licensed options with a Cloud Pharmacy clinician in the meantime.
Why individual results differ
Several things shape where someone falls relative to an average 1. The dose reached and tolerated, how consistently the medicine is taken, diet and activity, the starting point and other health factors all play a part, which is why two people can have quite different experiences on the same medicine 1.
For an oral semaglutide, there is an added factor: because absorption depends on taking it correctly, consistent administration could influence how much effect comes through 13. That is one more reason results would be individual rather than uniform 3.
This is why comparing your own progress to a headline average, or to someone else's experience, can be misleading and demoralising 1. The more useful comparison is your own trend over time, discussed with a prescriber, which is how the licensed medicines are monitored 1.
How the licensed injection's results are framed
For the licensed Wegovy injection, the product information reports average weight reduction from its trials, achieved over an extended treatment period alongside diet and activity 1. Those averages are the basis for the figures people associate with semaglutide 1.
Crucially, those are the injection's trial averages, not the pill's, and this guide does not transfer them to the pill as if they were the same 13. They are useful for understanding how semaglutide results are framed, that is, as averages over time with diet and activity, but not as a stand-in for the pill's own UK figures 1.
Our guide on how much weight you can lose explores realistic expectations for the licensed medicines, framed around averages and variation 1. It is a useful read for understanding results sensibly while the pill's own UK picture is awaited 13.
The honest bottom line on results
The honest bottom line is that this guide does not present a Wegovy pill weight-loss figure as UK fact, because the pill is not yet UK-licensed and any percentage sits outside the regulated UK sources 3. Results from weight-loss medicines are individual, not guarantees, and trial figures are averages 1.
The pill's UK results picture, including any figures and how they apply, would come from its licence and NICE once approved, and a clinician would set realistic expectations for your circumstances 32. That is the source to rely on rather than a pre-licence number 3.
Until then, the useful mindset is to understand results as averages with wide variation, achieved alongside diet and activity, and to follow the licensed options with a prescriber if you want treatment now 12. Our guide on choosing a weight-loss treatment covers what is available today 1.
Keeping the result, not just reaching it
A realistic results picture for any semaglutide includes what happens around stopping 1. Semaglutide reduces appetite while you take it, so appetite, and the factors behind weight, tend to return when treatment stops, which is why the habits built alongside it matter for maintaining any result 1.
That is part of why this guide frames results around the whole journey rather than a single peak figure 1. The diet and activity the medicine is licensed to accompany are what give the best chance of holding onto progress, and they are worth building from the start 12.
It would be no different for an oral form 13. Whatever the pill's UK results picture turns out to be, the durability of any result would still depend on the habits built alongside it, because the medicine supports change rather than locking it in permanently 1.
Our guide on weight regain after stopping covers this in detail 1. The realistic headline is that semaglutide can support meaningful change, that averages are not guarantees, and that what you do alongside it shapes both the result and how well it lasts 13.
Reading results coverage sensibly
Because the pill is generating headlines, it is worth knowing how to read results coverage 3. A striking percentage in a news story is usually a trial average from a particular study population, reported before any UK assessment, so it is best read as 'what one trial averaged' rather than 'what the pill does in the UK' 13.
Fair questions to ask of any figure are where it comes from, over what time period, in whom, and whether UK regulators have assessed it 3. For the pill today, the honest answers are that it is not yet UK-licensed and the UK assessment is not complete, which is why this guide does not adopt the number 13.
This is not a reason to dismiss the research, but a reason to hold it in proportion until the UK picture is settled 3. Optimism about a promising option is reasonable; treating a pre-licence figure as a personal guarantee is not 13.
When a UK licence and NICE assessment exist, the results picture will be clearer and specific to the UK, and a clinician can set realistic expectations for you against it 23. That is the point at which a number becomes genuinely useful rather than just eye-catching 13.
It is also worth being a little wary of comparisons between the pill and the injection, or between the pill and other medicines, based on pre-licence figures 13. Such comparisons depend on the specifics of each trial and population, so they can mislead until there are settled, comparable UK figures, and a clinician is better placed than a headline to put any comparison in context for you 12. The honest stance is to treat all such comparisons as provisional until the UK evidence is in 3.
Frequently asked questions
How much weight will I lose on the Wegovy pill?
This guide does not present a figure as UK fact, because the pill is not yet UK-licensed and any percentage comes from outside the regulated UK sources 3. Results from weight-loss medicines are individual and depend on diet and activity 1.Why won't you state the trial result?
Because trial figures reported elsewhere are not the same as a UK-confirmed results picture, which would come from the pill's UK licence and NICE once approved 3. Trial figures are also averages, not guarantees for any individual 1.Are the injection's results the same as the pill's?
This guide does not transfer the injection's trial averages to the pill, because they are different products and the pill's UK figures do not yet exist 13. The injection's framing is useful only for understanding how semaglutide results are presented 1.Do I still need to diet and exercise?
Yes. Semaglutide is licensed as an adjunct to a reduced-calorie diet and increased physical activity, and trial results reflect that whole package, not the medicine alone 12. The result depends on what you do alongside it 1.Why do results vary so much between people?
Dose, consistency, diet and activity, starting point and other health factors all affect where someone falls relative to an average 1. For an oral form, correct administration could also influence how much effect comes through 13.Where will the real UK results picture come from?
From the pill's UK licence and NICE assessment once approved, with a clinician setting realistic expectations for your circumstances 32. That is more reliable than a pre-licence figure from trials or overseas 3.Your next step
This guide does not present a Wegovy pill weight-loss figure as UK fact, because the pill is not yet UK-licensed and any percentage circulating comes from outside the regulated UK sources. Results from any weight-loss medicine are individual rather than guaranteed, and trial figures are averages across groups that hide a wide spread, achieved alongside the reduced-calorie diet and increased activity semaglutide is licensed to accompany.
The injection's trial averages are useful only for understanding how semaglutide results are framed, not as a stand-in for the pill's own UK figures, which would come from its licence and NICE once approved. Until then, read results as averages with wide variation, focus on the diet and activity that shape your own outcome, and follow the licensed options with a prescriber if you want treatment now. A clinician would set realistic expectations for your circumstances once a licensed product is available.
Disclaimer
This guide is for general information only and does not constitute medical advice, diagnosis or treatment. The information here describes general clinical context based on UK regulatory sources cited above; it is not a recommendation for any specific medicine or treatment, which can only be made by a prescriber following individual assessment.
If you are considering treatment, speak to your GP or pharmacist, or arrange a consultation with a Cloud Pharmacy clinician. Prescription-only medicines are issued only after clinical assessment and where appropriate.
If you experience side effects from any medicine, you can report them through the Yellow Card scheme at yellowcard.mhra.gov.uk.
References
- Wegovy SmPC 4.1/5.1 (licensed INJECTION: average weight reduction in trials over an extended period; adjunct to reduced-calorie diet and increased physical activity; individual variation; used to explain how semaglutide results are framed, NOT transferred to the pill)
- Semaglutide (used with diet and exercise; general framing; realistic expectations)
- General UK framing; Wegovy pill not UK-licensed (June 2026); trial/overseas weight-loss figures out-of-corpus and NOT asserted; UK results picture would come from its licence and NICE
